Celgene Corporation CELG and Acceleron Pharma Inc.
XLRN today announced preliminary results from an ongoing
long-term Phase 2 extension study in patients with lower risk
myelodysplastic syndromes (MDS) at the 57th American Society
of Hematology (ASH) Annual Meeting and Exposition. Results highlighted
in an oral presentation showed that patients with lower risk MDS treated
with luspatercept in the long-term extension study achieved and
maintained increased hemoglobin levels and transfusion independence.
Celgene and Acceleron are jointly developing luspatercept.
"These results for longer-term luspatercept treatment in lower risk MDS
patients are very exciting," said Aristoteles Giagounidis, M.D., Ph.D.,
Head of the Department of Oncology, Haematology, and Palliative Care at
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in